Swedish Orphan Biovitrum Debt Issuance/Retirement Net - Total 2019-2024 | BIOVF

Swedish Orphan Biovitrum debt issuance/retirement net - total for the twelve months ending September 30, 2024 was $0.202B, a 91.94% decline year-over-year.

  • Swedish Orphan Biovitrum annual debt issuance/retirement net - total for 2023 was $1.045B, a 513.36% decline from 2022.
  • Swedish Orphan Biovitrum annual debt issuance/retirement net - total for 2022 was $-0.253B, a 47.39% decline from 2021.
  • Swedish Orphan Biovitrum annual debt issuance/retirement net - total for 2021 was $-0.481B, a 180.92% increase from 2020.

Swedish Orphan Biovitrum Debt Issuance/Retirement Net - Total 2019-2024 | BIOVF

  • Swedish Orphan Biovitrum annual debt issuance/retirement net - total for 2023 was $1.045B, a 513.36% decline from 2022.
  • Swedish Orphan Biovitrum annual debt issuance/retirement net - total for 2022 was $-0.253B, a 47.39% decline from 2021.
  • Swedish Orphan Biovitrum annual debt issuance/retirement net - total for 2021 was $-0.481B, a 180.92% increase from 2020.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.5B
Amgen (AMGN)$159.7B
Gilead Sciences (GILD)$139.4B
Vertex Pharmaceuticals (VRTX)$121.3B
Bristol Myers Squibb (BMY)$96.3B
GSK (GSK)$78.4B
CSL (CSLLY)$77.4B
Regeneron Pharmaceuticals (REGN)$61.6B
Alnylam Pharmaceuticals (ALNY)$41.2B
Argenex SE (ARGX)$34.4B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$20.4B
Biogen (BIIB)$19.5B
Insmed (INSM)$19.3B
Illumina (ILMN)$15.6B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.8B
Incyte (INCY)$13.5B
Moderna (MRNA)$12.7B
Exelixis (EXEL)$12.4B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Exact Sciences (EXAS)$10.2B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.4B
Bio-Techne Corp (TECH)$8.2B
Roivant Sciences (ROIV)$7.9B
Regencell Bioscience Holdings (RGC)$7.3B
Legend Biotech (LEGN)$7.2B